Human adipose depots’ diverse functions and dysregulations during cardiometabolic disease

Human adipose depots’ diverse functions and dysregulations during cardiometabolic disease

Introduction

Obesity, with its negative impact on cardiometabolic diseases, is a major and growing global health issue. Understanding underlying mechanisms that could be targeted is therefore important. Fat storage in adipose tissue can during energy excess be expanded to extreme measures, a condition known as obesity. However, less visible is the dysregulation and loss of adipocyte function that accompanies obesity to various extent in an individualized manner. Adipose tissue is commonly divided into white, beige and brown adipose tissue. However, when discussing distinct adipose functions, these terms are incomplete. Adipocytes exist as different subtypes and have specialized functions, which are largely separated by their anatomical organization into adipose depots. Importantly, adipocytes are even found to have distinct functions within depots, displaying a wide heterogeneity at single cell resolution1. Analyses of human cohorts, discussed below, suggest that there is a fundamental connection between adipocyte functionality and cardiometabolic health.

Multiple studies have demonstrated that hip to waist ratio or waist circumference is a far more accurate predictor of cardiometabolic disease than body mass index (BMI)2,3. Accordingly, abdominal obesity is associated with a reduction in adipogenic capacity (i.e. the capacity to form new adipocytes) in the subcutaneous adipose tissue depot, in primarily the gluteofemoral region4, and a reciprocally increased lipid storage and increased low grade inflammation in the visceral adipose depot5,6. At the same time, cardiometabolic disease is also associated with a loss of thermogenic activity in the supraclavicular and deep neck7. Thus, adipose tissue across depots is functionally compromised during cardiometabolic disease.

The explanation for what is causing adipocyte loss of specialization during cardiometabolic disease and whether it is causative or a consequence, remains elusive. Genetic predisposition8 and genetic interaction with environmental factors including diet, stress, smoking, sleeping patterns and infrastructures discouraging physical activity and generating unhealthy eating patterns, are all contributing to a physiological challenge of excess lipids and glucose that will affect us differently dependent on genetic make-up.

In the current review, we will not discuss genetic and environmental interactions, but instead focus on the differential dysregulations occurring in each of three major adipose tissue depots that have most frequently been studied in relation to cardiometabolic disease (Fig. 1): supraclavicular/ deep neck brown adipose tissue (BAT), omental visceral adipose tissue, and gluteofemoral subcutaneous adipose tissue. We will discuss adipose depot-specific dysregulations and consequences across depots that can contribute to the progression of cardiometabolic disease.

Fig. 1: Loss of functions of adipose tissues in relation to metabolic dysfunction.
Human adipose depots’ diverse functions and dysregulations during cardiometabolic disease

In a healthy state (a), thermogenic fat (brown adipose tissue) is sympathetically activated in response to cold, producing heat and taking up glucose and fatty acids from the circulation. In the visceral depot, immunogenic fat interacts with the immune system to battle inflammation and infections. Subcutaneous adipose tissue is highly lipogenic and provides safe energy storage. Several factors including hormonal changes, genetic predisposition, environmental factors and physical inactivity, contributes to metabolic dysfunction (b). Thermogenic depots lose their capacity of substrate uptake and thermogenesis. Ectopic fat is accumulating in the visceral adipose depot, accompanied by a chronically inflammatory state. Subcutaneous adipocytes reach their maximal capacity of fat storage and adipogenesis is downregulated, diminishing the potential of safe lipid storage and accelerating ectopic fat accumulation.

Full size image

Dysregulation of thermogenic and immunogenic functions in visceral adipose tissue

Visceral adipose tissue (VAT) is a collection of adipose depots surrounding the inner organs. These include the intraperitoneal depots (omental and mesenteric), which drain into the hepatic portal vein. It also includes the retroperitoneal, which is located behind the abdominal space, in the peritoneal cavity where the perirenal adipose depot is found. Whereas perirenal fat is classified as a brown adipose depot9 and has been frequently observed as activated along with supraclavicular and deep neck regions10, omental and mesenteric fat are not thermogenic under normal conditions. Nevertheless, thermogenic adipocytes have been detected at least in the omental fat among other adipocyte subtypes when the tissue has been studied at single cell resolution11,12. This aligns well with the observation that the whole visceral compartment can differentiate into highly thermogenic fat during pathological conditions such as pheochromocytoma (tumor leading to overproduction of norepinephrine from the adrenal gland)13. As discussed in further detail below, thermogenic adipocytes become dysfunctional during cardiometabolic disease7.

The omental adipose tissue has immunogenic capacity and interacts with the immune system during abdominal inflammation. Interestingly, adipose progenitors isolated from omental adipose tissue display a more immunogenic transcription profile and commit less to adipogenic differentiation compared to subcutaneous adipocytes14. The limited adipogenesis in cells from the omental depot is further emphasized by differentiating adipose progenitors from the visceral depot having a lower proportion of adipogenic cells compared to cells isolated from subcutaneous, supraclavicular and perirenal depots, when analyzed at a single cell level15. In vivo, the omental depot is highly vascularized and appears to play an important part in mobilizing the immune defense against pathogens as well as during non-infectious inflammation16,17. During these conditions, the omental fat relocates to the affected area and encapsulates it. A dramatic increase in immune cell number has been observed in the omentum attaching to the inflamed and/or infected site18. During obesity- induced cardiometabolic disease, an expansion of ectopic fat storage in the visceral depots typically occur19. This fat accumulation is associated with a chronic low-grade inflammation20, hallmarked by increased infiltration and residency of pro-inflammatory immune cells into the adipose tissue. Importantly, inflammatory cytokines including TNF have inhibitory effects on adipogenesis14, and an inflamed adipose tissue can thus impair healthy adipogenesis and further accelerate ectopic fat storage. Whether this increased ectopic fat storage in turn hampers the capacity of omental adipose tissue to react properly to infection and regulate inflammation remains largely unexplored. In conclusion, human visceral adipose tissue during healthy conditions, encompasses thermogenic and immunogenic capacities, which are both dysregulated during cardiometabolic diseases in favor of lipid storage, inactivate thermogenic capacity, and onset of low-grade inflammation. The reason behind ectopic fat storage in the visceral depots might be related to a dysfunctional subcutaneous adipogenesis, expansion and signaling in response to excess energy intake, which is further discussed below.

Exhaustion of subcutaneous adipose tissue and loss of adipogenic capacity

In humans, subcutaneous fat has no contact with inner organs and has evolved to exhibit an extraordinary capacity of safe energy storing. Fat accumulation in the gluteofemoral subcutaneous adipose tissue has been identified as particularly healthy and associated with insulin sensitivity4. Insulin stimulates lipogenesis and plays an important role in adipogenesis21. In accordance, insulin resistance and type 2 diabetes are associated with premature adipose cell senescence along with reduced adipogenesis22,23,24. The reduced adipogenic capacity is in turn associated with increased adipocyte hypertrophy24, which correlate with elevated plasma insulin levels and reduced insulin sensitivity25.

Another important regulator of adipogenesis is estrogen which appears crucial for maintenance of the gluteofemoral subcutaneous adipose tissue26. In women, estrogen promotes adipogenesis specifically in the gluteofemoral depot due to higher expression of the estrogen receptor in the gluteofemoral adipose progenitor cells27, while inhibiting fat accumulation in visceral regions28. This relationship is emphasized by the body fat redistribution occurring during menopause when estrogen levels decrease29. In accordance, women’s cardiometabolic health falls drastically following menopause30.

Additional observations emphasize subcutaneous adipose tissue as a gate keeper of cardiometabolic health. For example, a compensatory increase in visceral fat mass has been observed 6 months after liposuction of subcutaneous adipose tissue31. Moreover, patients suffering from lipodystrophy, failing to store fat in subcutaneous depots, exhibit both visceral fat mass expansion and increased cardiometabolic burden32.

Whereas safe lipid storage is a key function of the subcutaneous adipose tissue, a loss of functional adipocytes is likely also affecting the adipokine signature, which represent a crucial feedback mechanism for regulating food intake, reviewed in detailed elsewhere33.

In conclusion, preserving functionality and sustained safe storage capacity of free fatty acids in the subcutaneous adipose depot is fundamental for avoiding ectopic fat accumulation in the visceral regions. Individual capacity for expanding subcutaneous adipose tissue before reaching adipose tissue exhaustion and dysregulation is a possible explanation to why obesity is not always leading to cardiometabolic disease.

Loss of thermogenic function in brown adipose tissue during cardiometabolic disease

Humans are among the mammals that still possess the capacity of activating thermogenesis through mitochondrial uncoupling protein 134,35. This occurs via sympathetic activation in response to cold, mainly in adipose tissue in the supraclavicular and deep neck region, along the spinal cord and in the perirenal adipose tissue surrounding the kidneys10. When adipose progenitors are isolated from surgical biopsies from these regions, they differentiate into thermogenic brown adipocytes in vitro, regardless of the thermogenic in vivo phenotype9,36. However, in vivo this function is gradually declining with age and even more severely and rapidly with cardiometabolic diseases7. Thermogenic activity was found to be reduced with obesity, while fat accumulation in brown adipose tissue (BAT) was higher compared to BAT of normal weight subjects10. Importantly, in larger cohorts, BAT activity correlates with insulin sensitivity and cardiometabolic health independently of BMI7. Whether this correlation represents a functional role of BAT in the maintenance of a healthy metabolism in humans, is currently unclear.

In mice, diet-induced obesity increase BAT inflammation, promotes white adipocyte infiltration, distorts BAT function, and inhibits tissue glucose uptake37, while BAT transplantation from healthy wild type mice into ob/ob mice improves insulin sensitivity and counteracts hepatic steatosis38. In fact, increasing BAT activity in mice directly counteracts obesity. Nevertheless, considering the differences between mice and humans in lipid storage capacity, thermogenic capacity and metabolism, it is difficult to directly translate these observations to humans. Given the smaller proportions of BAT present in humans in comparison to mice, there is likely an alternative explanation to its correlation with cardiometabolic health.

First, the gold standard for measuring BAT activity in humans is through FDG-PET/CT-scanning, measuring the glucose uptake in BAT during cold exposure as an estimate of BAT activation39. With an increased lipid accumulation in BAT, it is possible that the glucose uptake is severely reduced. Another potential explanation is altered batokine secretion pattern. Brown and white adipose tissue secrete metabolic regulators33,40. Thus, regardless of whether adult humans have enough BAT to significantly affect energy expenditure through cold exposure, BAT might still play a role in regulating metabolic homeostasis in human through organ crosstalk41,42. In conclusion, the correlation between reduced BAT activity during cardiometabolic disease, how this relates to the overall dysfunction of other adipose depots, and how it impacts whole body metabolism remains to be explored.

Concluding remarks and perspectives

We here discuss the loss of adipocyte specialization in three major adipose depots in humans and how this relates to the development of cardiometabolic disease. Expansion of the visceral adipose tissue, accelerating low-grade inflammation, is a key driver of insulin resistance. At the same time, losing adipogenic and storage capacity in subcutaneous depots and thermogenic capacity in BAT, will accelerate lipid deposition in the visceral depot. Indeed, emerging reports about futile cycling, reviewed elsewhere43 demonstrate capacity for energy dissipation in adipose depots other than BAT as well. In addition, loss of adipocyte specialization should be expected to also affect adipocyte subtype secretomes, potentially causing disturbances in whole body energy homeostasis. Future studies should investigate depot-specific regulation of adipocytes in relation to metabolic phenotypes for discovering new pathways and candidates with the ultimate goal of reversing cardiometabolic disease and reinstall adipose tissue as a functional regulator of metabolic homeostasis.

Related Articles

Implantation of engineered adipocytes suppresses tumor progression in cancer models

Tumors exhibit an increased ability to obtain and metabolize nutrients. Here, we implant engineered adipocytes that outcompete tumors for nutrients and show that they can substantially reduce cancer progression, a technology termed adipose manipulation transplantation (AMT). Adipocytes engineered to use increased amounts of glucose and fatty acids by upregulating UCP1 were placed alongside cancer cells or xenografts, leading to significant cancer suppression. Transplanting modulated adipose organoids in pancreatic or breast cancer genetic mouse models suppressed their growth and decreased angiogenesis and hypoxia. Co-culturing patient-derived engineered adipocytes with tumor organoids from dissected human breast cancers significantly suppressed cancer progression and proliferation. In addition, cancer growth was impaired by inducing engineered adipose organoids to outcompete tumors using tetracycline or placing them in an integrated cell-scaffold delivery platform and implanting them next to the tumor. Finally, we show that upregulating UPP1 in adipose organoids can outcompete a uridine-dependent pancreatic ductal adenocarcinoma for uridine and suppress its growth, demonstrating the potential customization of AMT.

Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions

The worldwide health emergency of obesity is closely connected to how dietary fats are metabolized, whereas the process is significantly influenced by pancreatic lipase (PL), an enzyme critical for lipid hydrolysis into fatty acids. This narrative review employs a methodological approach utilizing literature searches of PubMed data up to March 2024. The search term criteria encompasses keywords related to the role, mechanism, challenges, and current and future treatments of pancreatic lipase in obesity with an overall references is 106. This paper offers a comprehensive explanation of the role of PL, underlining its significance in the digestive process and lipid imbalances that contribute to obesity and by extension, its impact on obesity development and progression. Additionally, it delves into the dual functionality of the pancreas, emphasizing its impact on metabolism and energy utilization which, when dysregulated, promotes obesity. A focal point of this review is the investigation into the efficacy, challenges, and adverse effects of current pancreatic lipase inhibitors, with orlistat being highlighted as a primary current drug delivery. By discussing advanced obesity treatments, including the exploration of novel anti-obesity medications that target specific biological pathways, this review underscores the complexity of obesity treatment and the necessity for a multifaceted approach. In conclusion, this paper emphasizing the importance of understanding the role of enzymes like pancreatic lipase mechanistic and adopting a multidisciplinary approach to treatment and side effects of current obesity drugs and explore new emerging therapeutic strategies for more effective obesity management.

The brown fat-specific overexpression of RBP4 improves thermoregulation and systemic metabolism by activating the canonical adrenergic signaling pathway

Retinol-binding protein 4 (RBP4), the sole specific carrier for retinol (vitamin A) in circulation, is highly expressed in liver and adipose tissues. Previous studies have demonstrated that RBP4 plays a role in cold-mediated adipose tissue browning and thermogenesis. However, the role of RBP4 in brown adipose tissue and its metabolic significance remain unclear. Here we generated and studied transgenic mice that express human RBP4 (hRBP4), specifically in brown adipocytes (UCP1-RBP4 mice), to better understand these uncertainties. When fed a chow diet, these mice presented significantly lower body weights and fat mass than their littermate controls. The UCP1-RBP4 mice also showed significant improvements in glucose clearance, enhanced energy expenditure and increased thermogenesis in response to a cold challenge. This was associated with increased lipolysis and fatty acid oxidation in brown adipose tissue, which was attributed to the activation of canonical adrenergic signaling pathways. In addition, high-performance liquid chromatography analysis revealed that plasma RBP4 and retinol levels were elevated in the UCP1-RBP4 mice, whereas their hepatic retinol levels decreased in parallel with a chow diet. Steady-state brown fat levels of total retinol were significantly elevated in the UCP1-RBP4 mice, suggesting that their retinol uptake was increased in RBP4-expressing brown adipocytes when fed a chow diet. These findings reveal a critical role for RBP4 in canonical adrenergic signaling that promotes lipid mobilization and oxidation in brown adipocytes, where the harnessed energy is dissipated as heat by adaptive thermogenesis.

Separate orexigenic hippocampal ensembles shape dietary choice by enhancing contextual memory and motivation

The hippocampus (HPC) has emerged as a critical player in the control of food intake, beyond its well-known role in memory. While previous studies have primarily associated the HPC with food intake inhibition, recent research suggests a role in appetitive processes. Here we identified spatially distinct neuronal populations within the dorsal HPC (dHPC) that respond to either fats or sugars, potent natural reinforcers that contribute to obesity development. Using activity-dependent genetic capture of nutrient-responsive dHPC neurons, we demonstrate a causal role of both populations in promoting nutrient-specific intake through different mechanisms. Sugar-responsive neurons encoded spatial memory for sugar location, whereas fat-responsive neurons selectively enhanced the preference and motivation for fat intake. Importantly, stimulation of either nutrient-responsive dHPC neurons increased food intake, while ablation differentially impacted obesogenic diet consumption and prevented diet-induced weight gain. Collectively, these findings uncover previously unknown orexigenic circuits underlying macronutrient-specific consumption and provide a foundation for developing potential obesity treatments.

Transcriptional dynamics in type 2 diabetes progression is linked with circadian, thermogenic, and cellular stress in human adipose tissue

The prevalence of type 2 diabetes (T2D) has increased significantly over the past three decades, with an estimated 30–40% of cases remaining undiagnosed. Brown and beige adipose tissues are known for their remarkable catabolic capacity, and their ability to diminish blood glucose plasma concentration. Beige adipose tissue can be differentiated from adipose-derived stem cells or through transdifferentiation from white adipocytes. However, the impact of T2D progression on beige adipocytes’ functional capacity remains unclear. Transcriptomic profiling of subcutaneous adipose tissue biopsies from healthy normal-weight, obese, prediabetic obese, and obese subjects diagnosed with T2D, reveals a progressive alteration in cellular processes associated with catabolic metabolism, circadian rhythms, thermogenesis-related signaling pathways, cellular stress, and inflammation. MAX is a potential transcription factor that links inflammation with the circadian clock and thermogenesis during the progression of T2D. This study unveils an unrecognized transcriptional circuit that increasingly disrupts subcutaneous adipose tissue oxidative capacity during the progression of T2D. These findings could open new research venues for developing chrono-pharmaceutical strategies to treat and prevent T2D.

Responses

Your email address will not be published. Required fields are marked *